|
Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
faricimab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].
|
| No information available. |
Summary of Clinical Use  |
| Faricimab was evaluated for efficacy in eye diseases that involve aberrant vascularisation, including diabetic macular edema (DME), wet age-related macular degeneration (wAMD) and branch retinal vein occlusion (BRVO). Phase 2 studies demonstrated clinical efficacy for the treatment of wAMD, and superiority to the anti-VEGF-A biologic ranibizumab in the management of DME [1]. Faricimab (Vabysmo®) was FDA approved in January 2022, as a treatment for both wAMD and DME. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03823287 | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT04740905 | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT03622580 | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT04432831 | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT03038880 | Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration | Phase 2 Interventional | Hoffmann-La Roche | 2 | |
| NCT02699450 | A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema | Phase 2 Interventional | Hoffmann-La Roche | 1,5 | |
